OC
OCC.AU Orthocell Ltd
- Market cap
- AUD 150M
- P/E
- -
- P/B
- 4.35x
- ROE
- -40.4%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is OCC.AU undervalued?
Graham numberThe Graham number of Orthocell Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orthocell Ltd fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-40.4%), below 10%.
ROA 1/1
Return on assets (-25.4%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-37.7%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 39.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (4.5%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 3.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (4.4x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Orthocell Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and…
Full company profileOrthocell Ltd financial statements
Orthocell Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 530K | 619K | 946K | 720K | 1.02M | 1.53M | 4.24M | 5.32M | 7.55M | 11.4M |
| Gross Profit | 91.7K | 149K | 213K | -6.40K | 300K | 833K | 3.06M | 3.69M | 4.80M | 3.68M |
| Operating Income | -6.16M | -8.03M | -8.52M | -9.47M | -11.7M | -11.5M | -10.3M | -11.7M | -14.0M | -18.4M |
| EBITDA | -6.52M | -8.29M | -8.53M | -9.25M | -11.7M | -11.5M | -10.3M | -11.7M | -13.4M | -17.5M |
| Net Income | -4.18M | -5.76M | -5.85M | -6.15M | -9.04M | -9.11M | -6.25M | -7.18M | -8.57M | -13.9M |
| EPS | -0.04 | -0.05 | -0.05 | -0.04 | -0.05 | -0.05 | -0.03 | -0.04 | -0.04 | -0.05 |
| Balance Sheet | ||||||||||
| Total Assets | 7.16M | 5.23M | 13.6M | 23.2M | 19.3M | 37.9M | 29.6M | 26.6M | 35.2M | 54.8M |
| Total Liabilities | 2.45M | 2.86M | 2.87M | 2.27M | 2.46M | 28.0M | 23.5M | 22.1M | 20.7M | 20.4M |
| Shareholders' Equity | 4.71M | 2.37M | 10.7M | 20.9M | 16.9M | 9.90M | 6.15M | 4.53M | 14.6M | 34.4M |
| Cash & Short-term Investments | 5.05M | 2.91M | 11.2M | 20.4M | 16.3M | 11.0M | 24.8M | 20.6M | 28.6M | 44.2M |
| Total Debt | - | - | 501K | 501K | 622K | 508K | 562K | 690K | 577K | 1.55M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.56M | -4.64M | -4.18M | -5.26M | -4.63M | -6.26M | 14.6M | -6.51M | -8.68M | -13.3M |
| Capital Expenditure | 108K | 87.2K | 14.2K | 55.2K | 189K | 535K | 632K | 942K | 359K | 1.11M |
| Free Cash Flow | -3.66M | -4.73M | -4.19M | -5.31M | -4.82M | -6.80M | 14.0M | -7.45M | -9.04M | -14.4M |
| Ratios | ||||||||||
| ROE | -88.6% | -242.7% | -54.6% | -29.4% | -53.6% | -91.9% | -101.6% | -158.4% | -58.8% | -40.4% |
| ROA | -58.4% | -110.1% | -43.0% | -26.5% | -46.8% | -24.0% | -21.1% | -27.0% | -24.3% | -25.4% |
| Net Profit Margin | -788.5% | -929.8% | -618.9% | -854.9% | -887.8% | -594.5% | -147.3% | -135.1% | -113.5% | -122.0% |
| Debt to Equity | - | - | 0.05x | 0.02x | 0.04x | 0.05x | 0.09x | 0.15x | 0.04x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Orthocell Ltd dividends
Orthocell Ltd has not paid dividends in the last 10 fiscal years.
Who owns Orthocell Ltd
- Insiders 16.98%
- Institutions 4.04%
- Public & others 78.98%
- Shares outstanding 272M
- Free float 228M
Orthocell Ltd company profile
- Company name
- Orthocell Ltd
- Ticker
- OCC.AU
- ISIN
- AU000000OCC6
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 161 Campus Drive, Murdoch, WA, Australia, 6150
- Phone
- 61 8 9360 2888
- Website
- orthocell.com
About Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Orthocell Ltd management
7- Mr. Paul Frederick AndersonCEO, MD & Executive Director · born 1966
- Mr. Jim PiperChief Financial Officer
- Prof. Ming Hao ZhengChief Scientific Officer and Member of Medical & Scientific Advisory Board
- Mr. Tony MacintyreChief Technical Operations Officer
- Mr. Adam WoodChief Commercial Officer
- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963
- John WalkerVice President of Sales USA